Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C26449
http://purl.obolibrary.org/obo/NCIT_C26449
Preferred Name

Abagovomab
Definitions
A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.
prefLabel
Abagovomab
label
Abagovomab
PDQ_Closed_Trial_Search_ID
299488
code
C26449
Has_Target
prefixIRI
NCIT:C26449
in_subset
Display_Name
Abagovomab
Preferred_Name
Abagovomab
FDA_UNII_Code
3YK0326U7X
Contributing_Source
CTRP
FDA
Maps_To
Abagovomab
CAS_Registry
792921-10-9
NCI_Drug_Dictionary_ID
299488
Legacy Concept Name
Monoclonal_Antibody_ACA125_Anti-Idiotype_Vaccine
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
299488
Semantic_Type
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C1832044
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display